BRIEF-Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients

Reuters01-22

BRIEF-<a href="https://laohu8.com/S/HOTH">Hoth Therapeutics</a> Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients

Jan 22 (Reuters) - Hoth Therapeutics Inc HOTH.O:

HOTH THERAPEUTICS DELIVERS 100% CLINICAL RESPONSE WITH ~50% REDUCTION IN DISEASE SEVERITY IN OPEN-LABEL PK COHORT OF EGFR-TREATED CANCER PATIENTS
HOTH THERAPEUTICS INC - HT-001 WELL TOLERATED WITH NO UNEXPECTED SAFETY SIGNALS
HOTH THERAPEUTICS INC - ADDITIONAL ENDPOINTS SHOW ~34% IMPROVEMENT IN ONCOLOGY TOXICITY

Source text: ID:nPn65gKMBa

Further company coverage: HOTH.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605492722?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 22:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605492722","market":"us","top_or_hot":-1,"title":"BRIEF-Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients</title></head><body><p><span>Jan 22 (Reuters)</span><span> - </span>Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>HOTH.O</span>:</p><ul><li><p>HOTH THERAPEUTICS DELIVERS 100% CLINICAL RESPONSE WITH ~50% REDUCTION IN DISEASE SEVERITY IN OPEN-LABEL PK <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> OF EGFR-TREATED CANCER PATIENTS</p></li><li><p>HOTH THERAPEUTICS INC - HT-001 WELL TOLERATED WITH NO UNEXPECTED SAFETY SIGNALS</p></li><li><p>HOTH THERAPEUTICS INC - ADDITIONAL ENDPOINTS SHOW ~34% IMPROVEMENT IN ONCOLOGY TOXICITY</p></li></ul><p>Source text: <span>ID:nPn65gKMBa</span></p><p>Further company coverage: <span>HOTH.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-22 22:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients</title></head><body><p><span>Jan 22 (Reuters)</span><span> - </span>Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>HOTH.O</span>:</p><ul><li><p>HOTH THERAPEUTICS DELIVERS 100% CLINICAL RESPONSE WITH ~50% REDUCTION IN DISEASE SEVERITY IN OPEN-LABEL PK <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> OF EGFR-TREATED CANCER PATIENTS</p></li><li><p>HOTH THERAPEUTICS INC - HT-001 WELL TOLERATED WITH NO UNEXPECTED SAFETY SIGNALS</p></li><li><p>HOTH THERAPEUTICS INC - ADDITIONAL ENDPOINTS SHOW ~34% IMPROVEMENT IN ONCOLOGY TOXICITY</p></li></ul><p>Source text: <span>ID:nPn65gKMBa</span></p><p>Further company coverage: <span>HOTH.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HOTH","symbol_name":"Hoth Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nTUAXLYTG:1","article_id":"2605492722","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605492722","pubTimestamp":1769091694,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer PatientsJan 22 (Reuters) - Hoth Therapeutics Inc HOTH.O:H","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HOTH":"Hoth Therapeutics","BK4007":"制药"},"translate_title":"简介-Hoth Therapeutics在接受EGFR治疗的癌症患者的开放标签PK队列中提供了100%的临床缓解，疾病严重程度降低了约50%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":0.9},"content_text":"BRIEF-Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer PatientsJan 22 (Reuters) - Hoth Therapeutics Inc HOTH.O:HOTH THERAPEUTICS DELIVERS 100% CLINICAL RESPONSE WITH ~50% REDUCTION IN DISEASE SEVERITY IN OPEN-LABEL PK COHORT OF EGFR-TREATED CANCER PATIENTSHOTH THERAPEUTICS INC - HT-001 WELL TOLERATED WITH NO UNEXPECTED SAFETY SIGNALSHOTH THERAPEUTICS INC - ADDITIONAL ENDPOINTS SHOW ~34% IMPROVEMENT IN ONCOLOGY TOXICITYSource text: ID:nPn65gKMBaFurther company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605492722","isCrawlerRequest":true}